Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy.
α-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responses.
Editorial Comments: Is multiple sclerosis a neurodegenerative or inflammatory disease?
Pregnancy and multiple sclerosis: the children of PRIMS.
Medical image. Neuromyelitis optica masquerading as sepsis.
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Reply to the Comment by Yolcu et al. on Our Paper Entitled ´Evaluation of Choroidal Vascular Changes in Patients with Multiple Sclerosis Using Enhanced Depth Imaging Optical Coherence Tomography´.
The impact of microglial activation on blood-brain barrier in brain diseases.
Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: The impact of thalamic subnuclei on disability.
Lymphocytic hypophysitis associated with pediatric multiple sclerosis.
Neurological disorders and celiac disease.
Functional course of Progressive Multifocal Leukoencephalopathy.
Need for differentiation of real and clinical important change in research on responsiveness of walking outcome measures in multiple sclerosis.
High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory-thrombotic processes.
Erratum to: 'Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial'.
Tysabri® (natalizumab) data at ECTRIMS reaffirm positive effects of treatment for people with relapsing forms of MS
Proteomics Urine Analysis of Pregnant Women Suffering from Multiple Sclerosis.
Improved neurite outgrowth on central nervous system myelin substrate by siRNA-mediated knockdown of Nogo receptor.
Deciphering Depressive Mood in Relapsing-Remitting and Progressive Multiple Sclerosis and Its Consequence on Quality of Life.
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
Re. 'Doppler Ultrasound Examination of Multiple Sclerosis Patients and Control Participants: Inter-observer Agreement and Association with Disease'
Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions.
Validation of Social Media Analysis for Outcomes Research: Identification of Drivers of Switches between oral and Injectable Therapies for Multiple Sclerosis.
Requirement for safety monitoring for approved MS therapies - An overview.
Use of complementary and alternative medicine in patients with cancer or multiple sclerosis: possible public health implications.
Pages
« first
‹ previous
…
644
645
646
647
648
649
650
651
652
…
next ›
last »